Combination Therapy of Biologics With Traditional Agents in Psoriasis

Lyn C. Guenther, MD, FRCPC


Skin Therapy Letter. 2011;16(6) 

In This Article

Combination Therapy With Adalimumab (Humira®)

Calcipotriol + Betamethasone Dipropionate

Adalimumab used in combination with calcipotriol + betamethasone dipropionate (Dovobet®) showed a more rapid and higher PASI 75 response at week 4 (40.7% vs. 32.4%, p=0.021) compared with adalimumab monotherapy.[11] However, at week 16, there was no significant difference in PASI 75 response (64.8% with combination therapy vs. 70.9% with adalimumab monotherapy, p=0.086).


Adalimumab in combination with methotrexate results in down regulation of more inflammatory markers in psoriatic plaques than monotherapy with either agent.[12] In the ADEPT psoriatic arthritis trial, at week 48, PASI 50, 75, 90, and 100 response rates were greater in the with-methotrexate subgroups (n=29) compared to the adalimumab without methotrexate subgroup (n=40), but only the PASI 50 results were statistically significant (PASI 50 in 83% vs. 55 %, p<0.05).[13]


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.
Post as: